ViiV Seeks Speedy EMA Review For Last-Resort HIV Drug
US Filing For Fostemsavir Expected This Year
Executive Summary
ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.